Sugi Predict

Sugi Predict / Compounds / SCHEMBL17348266

SCHEMBL17348266

SCHEMBL17348266

O=C(O)c1cccc(-c2cccc(-c3n[nH]c(-c4ccccc4)n3)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 5/20 0.60
▸ NR1H3 Q13133 5/20 0.60
▸ NPC1 O15118 3/20 0.60
▸ RAB9A P51151 3/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ MAPT P10636 2/20 0.60
▸ HPGD P15428 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ KMO O15229 1/20 0.60
▸ ATAD2 Q6PL18 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ MAPK1 P28482 1/20 0.52
▸ MAP2K4 P45985 1/20 0.52
▸ MAPKAPK3 Q16644 1/20 0.52
▸ MAPK6 Q16659 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ HPGDS O60760 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24242695 0.94 NR1H2 (0.60) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL12171118 0.91 NR1H2 (0.64) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL12798250 0.88 NR1H2 (0.60) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17280074 0.87 NR1H2 (0.62) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17735337 0.86 NR1H2 (0.75) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17570207 0.86 NR1H2 (0.81) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL26478315 0.85 GRK6 (0.55) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17117704 0.82 NR1H2 (0.69) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17280046 0.82 NR1H2 (0.69) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL17280045 0.82 NR1H2 (0.75) NR1H2NR1H3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11447453-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2022-09-20 — — US disclosed
EP-3154954-B1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF SANFORD BURNHAM MED RES INST (US) 2022-02-09 — — EP disclosed
US-20200347021-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2020-11-05 — — US disclosed
US-20200347021-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2020-11-05 — — US disclosed
US-10597367-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-24 — — US disclosed
US-10597367-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-24 — — US disclosed
US-20190016715-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-01-17 — — US disclosed
US-20190016715-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-01-17 — — US disclosed
US-9969726-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-05-15 — — US disclosed
US-9969726-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-05-15 — — US disclosed
US-20170217951-A1 Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2017-08-03 — — US disclosed
US-20170217951-A1 Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2017-08-03 — — US disclosed
WO-2015191630-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347021-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF GRM3, GRM2, GRM1 NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885
US-20170217951-A1 Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof GRM3, GRM2, GRM1 NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885
US-11447453-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof GRM3, GRM2, GRM1 NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885
US-20190016715-A1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF GRM3, GRM2, GRM1 NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885
US-10597367-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof GRM3, GRM2, GRM1 NR1H2 637/4885NR1H3 825/4885NPC1 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.